JP6242388B2 - 前立腺ガンのバイオマーカー - Google Patents

前立腺ガンのバイオマーカー Download PDF

Info

Publication number
JP6242388B2
JP6242388B2 JP2015516469A JP2015516469A JP6242388B2 JP 6242388 B2 JP6242388 B2 JP 6242388B2 JP 2015516469 A JP2015516469 A JP 2015516469A JP 2015516469 A JP2015516469 A JP 2015516469A JP 6242388 B2 JP6242388 B2 JP 6242388B2
Authority
JP
Japan
Prior art keywords
seq
methylation
c1orf114
base pair
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015516469A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015527875A (ja
JP2015527875A5 (enExample
Inventor
ソレンセン,カリナ ダルスガード
ソレンセン,カリナ ダルスガード
ハルラップ,クリスタ
オーントフ,トーベン ファルック
オーントフ,トーベン ファルック
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aarhus Universitet
Original Assignee
Aarhus Universitet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aarhus Universitet filed Critical Aarhus Universitet
Publication of JP2015527875A publication Critical patent/JP2015527875A/ja
Publication of JP2015527875A5 publication Critical patent/JP2015527875A5/ja
Application granted granted Critical
Publication of JP6242388B2 publication Critical patent/JP6242388B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16HHEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/30ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/154Methylation markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Databases & Information Systems (AREA)
  • Primary Health Care (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Data Mining & Analysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015516469A 2012-06-14 2013-06-14 前立腺ガンのバイオマーカー Active JP6242388B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201270326 2012-06-14
DKPA201270326 2012-06-14
PCT/DK2013/050196 WO2013185779A2 (en) 2012-06-14 2013-06-14 Biomarkers for prostate cancer

Publications (3)

Publication Number Publication Date
JP2015527875A JP2015527875A (ja) 2015-09-24
JP2015527875A5 JP2015527875A5 (enExample) 2016-07-07
JP6242388B2 true JP6242388B2 (ja) 2017-12-06

Family

ID=48740787

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015516469A Active JP6242388B2 (ja) 2012-06-14 2013-06-14 前立腺ガンのバイオマーカー

Country Status (6)

Country Link
US (1) US10106854B2 (enExample)
EP (1) EP2861759B1 (enExample)
JP (1) JP6242388B2 (enExample)
AU (1) AU2013275761B2 (enExample)
CA (1) CA2876252A1 (enExample)
WO (1) WO2013185779A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3037545A1 (en) * 2014-12-23 2016-06-29 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin A DNA-methylation test for prostate cancer
CN107532124B (zh) 2015-03-27 2022-08-09 精密科学公司 检测食管疾病
CN106480169B (zh) * 2015-09-01 2019-10-08 杨小丽 人aqp10和sox17基因甲基化位点的检测和应用
CA3054836A1 (en) * 2017-02-28 2018-09-07 Mayo Foundation For Medical Education And Research Detecting prostate cancer
GB201816820D0 (en) 2018-10-16 2018-11-28 Univ York Diagnostic method
WO2020099277A1 (en) 2018-11-13 2020-05-22 Bracco Imaging Spa Gene signatures for the prediction of prostate cancer recurrence
CN109468381B (zh) * 2018-11-19 2022-11-25 兰州市第一人民医院 用于宫颈癌筛查的甲基化位点及其检测引物
EP3999662A1 (en) * 2019-07-19 2022-05-25 Vilnius University Characterization of prostate cancer using dna methylation assay system
CN113122636A (zh) * 2020-01-14 2021-07-16 上海鹍远生物技术有限公司 检测dna甲基化的试剂及用途
US20230167506A1 (en) * 2020-05-04 2023-06-01 Mayo Foundation For Medical Education And Research Detecting pancreatic neuroendocrine tumors
WO2021226110A1 (en) * 2020-05-05 2021-11-11 The Board Of Trustees Of The Leland Stanford Junior University Cell-free dna biomarkers and their use in diagnosis, monitoring response to therapy, and selection of therapy for prostate cancer
CN118685523B (zh) * 2024-08-26 2024-11-15 湖南宏雅基因技术有限公司 一种用于前列腺癌检测的生物标志物组合、引物探针组合物及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786146A (en) 1996-06-03 1998-07-28 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US6605432B1 (en) 1999-02-05 2003-08-12 Curators Of The University Of Missouri High-throughput methods for detecting DNA methylation
DE60232059D1 (de) * 2001-03-01 2009-06-04 Epigenomics Ag Verfahren zur entwicklung von gensätzen zu diagnostischen und therapeutischen zwecken auf grundlage des expressions- und methylierungsstatus der gene
WO2008143896A1 (en) * 2007-05-14 2008-11-27 The Johns Hopkins University Methylation markers for prostate cancer and methods of use
CN102308003A (zh) * 2008-08-05 2012-01-04 维里德克斯有限责任公司 前列腺癌甲基化分析法
EP3524697B1 (en) * 2009-01-07 2024-10-02 Myriad Genetics, Inc. Cancer biomarkers
US20100303795A1 (en) 2009-05-27 2010-12-02 Soerensen Karina Dalsgaard Marker of prostate cancer
WO2011027310A1 (en) * 2009-09-03 2011-03-10 Koninklijke Philips Electronics N.V. Novel tumor markers
WO2011037936A2 (en) * 2009-09-24 2011-03-31 Oregon Health & Science University Detection of dna methylation of tal1, erg and/or cd40 to diagnose prostate cancer
WO2011044902A1 (en) 2009-10-13 2011-04-21 Aarhus Universitet Tff3 hypomethylation as a novel biomarker for prostate cancer
WO2011112845A2 (en) * 2010-03-11 2011-09-15 Board Of Regents, The University Of Texas System Methods and compositions related to a multi-methylation assay to predict patient outcome
US20140094380A1 (en) * 2011-04-04 2014-04-03 The Board Of Trustees Of The Leland Stanford Junior University Methylation Biomarkers for Diagnosis of Prostate Cancer

Also Published As

Publication number Publication date
US10106854B2 (en) 2018-10-23
JP2015527875A (ja) 2015-09-24
US20150152507A1 (en) 2015-06-04
EP2861759A2 (en) 2015-04-22
WO2013185779A3 (en) 2014-02-06
CA2876252A1 (en) 2013-12-19
WO2013185779A2 (en) 2013-12-19
AU2013275761A1 (en) 2015-01-22
AU2013275761B2 (en) 2017-09-28
EP2861759B1 (en) 2025-06-04

Similar Documents

Publication Publication Date Title
JP6242388B2 (ja) 前立腺ガンのバイオマーカー
JP5415963B2 (ja) 新しい癌マーカー
JP6603232B2 (ja) 膀胱がんの監視、診断、およびスクリーニング方法
US20200347459A1 (en) Dna methylation biomarkers for bladder cancer
JP2019000112A (ja) 結腸直腸がんのエピジェネティックマーカー及び該マーカーを使用する診断法
JP2009528825A (ja) デュークスb大腸がんの再発を予測するための分子的解析
US20210222256A1 (en) Pancreatic cancer
US12252747B2 (en) Unbiased DNA methylation markers define an extensive field defect in histologically normal prostate tissues associated with prostate cancer: new biomarkers for men with prostate cancer
US20120135877A1 (en) DNA Methylation Markers For Prostate Cancer Field Defect
ES3036448T3 (en) A dna-methylation test for prostate cancer
US12071672B2 (en) Unbiased DNA methylation markers define an extensive field defect in histologically normal prostate tissues associated with prostate cancer: new biomarkers for men with prostate cancer
US20090186360A1 (en) Detection of GSTP1 hypermethylation in prostate cancer
Fang et al. Genome-wide analysis of aberrant DNA methylation for identification of potential biomarkers in colorectal cancer patients
WO2017119510A1 (ja) 乳がんの診断のための検査方法、遺伝子マーカー、および検査薬
WO2016044142A1 (en) Bladder cancer detection and monitoring
EP2978861B1 (en) Unbiased dna methylation markers define an extensive field defect in histologically normal prostate tissues associated with prostate cancer: new biomarkers for men with prostate cancer
WO2021014187A1 (en) Characterization of prostate cancer using dna methylation assay system
US20090186359A1 (en) Detecting prostate cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160518

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170404

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170925

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171017

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171107

R150 Certificate of patent or registration of utility model

Ref document number: 6242388

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250